Abstract Objective: Ewing sarcoma (EwS) is a bone and soft tissue cancer primarily driven by a FET: : ETS fusion protein, most commonly EWS: : FLI1. While localized tumors have a five-year survival rate of 70–80% with multimodal treatment, the prognosis for relapsed or metastatic disease remains dismal, with survival rates below 30%. Starting from a large, multi-institutional cohort of patient-derived transcriptomes, this study aims to identify prognostic markers and therapeutic vulnerabilities associated with transcriptionally distinct classes of EwS. Methods: To characterize the transcriptional heterogeneity of EwS tumors, we applied RACCOON, an unsupervised hierarchical clustering approach, to define distinct transcriptional subtypes. We then used OTTER, a tumor classifier, to assign tumors from validation cohorts and preclinical models to these subtypes. Single-cell RNA sequencing and commonly used in vitro EwS cell lines were analyzed to assess transcriptional variability at single-cell resolution and in experimental systems. Clinical outcome stratification was evaluated using independent validation cohorts. Subtype-specific gene dependencies were inferred by integrating transcriptional subtype classifications with genome-wide CRISPR screening data from the DepMap project. Results: Three distinct transcriptional subtypes of EwS were identified: EWS: : FLI1-high, mesenchymal-like, and muscle-like. The muscle-like group was more distinct from the other subtypes, potentially due to myofiber infiltration. The remaining tumors exhibited a continuum of transcriptional states between EWS: : FLI1-high and EWS: : FLI1-low/mesenchymal-like subtypes. Transcriptional variability driven by fusion activity was further observed to differ across single-cell datasets and preclinical models. In the validation cohort, mesenchymal-like tumors were associated with the poorest prognosis (35% five-year overall survival) and the highest metastatic potential. In vivo studies in patient-derived xenografts supported these findings. Integration of CRISPR screening data from DepMap revealed subtype-specific gene dependencies: EWS: : FLI1-high tumors showed sensitivity to Fanconi anemia pathway disruption, whereas mesenchymal-like tumors relied on distinct transcriptional regulators. Conclusion: We define three transcriptional subtypes of Ewing sarcoma, EWS: : FLI1-high, mesenchymal-like, and muscle-like, with distinct gene dependencies, metastatic potential, and clinical outcomes. Our findings provide a foundation for new diagnostic approaches and molecular subtype-specific treatment strategies in EwS. After further validation, this approach has the potential to inform clinical decision-making and enable more personalized management of patients with EwS. Citation Format: Dusan Pesic, Joshua O Nash, Pedro Lemos Ballester, Timmy Wen, Livia Garzia, David Malkin, Adam Shlien. Targetable gene dependencies in Ewing sarcoma subtypes abstract. In: Proceedings of the AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer— From Biology to Breakthrough Therapies; 2025 Sep 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85 (18Suppl₂): Abstract nr A015.
Building similarity graph...
Analyzing shared references across papers
Loading...
Dusan Pesic
Joshua O. Nash
Pedro L. Ballester
Cancer Research
McGill University
SickKids Foundation
Building similarity graph...
Analyzing shared references across papers
Loading...
Pesic et al. (Thu,) studied this question.
www.synapsesocial.com/papers/68d913b24ddcf71ba560c19d — DOI: https://doi.org/10.1158/1538-7445.pediatric25-a015
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: